Full Press Release Details
Bio Solutions Expects to Report Record Fiscal First Quarter 2026 Revenue of Over $1 Million, an Increase of Approximately 32% Sequentially
and 28% Year-Over-Year
Achieves Third Consecutive Quarter of Revenue Growth
Increase of Approximately 32% Sequentially and 28% Year-Over-Year Driven by New Customer Accounts and Strong Cartridge and Reader Sales
and Reader Revenue Up Approximately 43% and 23% Year-Over-Year Respectively
YORK, November 04, 2025 - Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical
technology company delivering intelligent, rapid, non-invasive testing solutions, today announced preliminary, unaudited revenue results
for the fiscal first quarter ended September 30, 2025.
started fiscal year 2026 on a strong note, generating over $1 million in revenue - a record for our Company and a significant milestone,"
said Harry Simeonidis, President and CEO of Intelligent Bio Solutions. "As new customer acquisitions accelerate, we are
seeing strong momentum in both cartridge and reader sales, with cartridge revenue up approximately 43% year- over-year and reader revenue
up approximately 23% year-over-year for the fiscal first quarter. These results represent a substantial improvement on the previous quarter,
demonstrating the strength of our business model and positioning us well for continued growth."
Company expects to report fiscal first quarter 2026 revenue growth of approximately 32% sequentially and 28% year-on-year. This represents
the third consecutive quarter of revenue growth and shows the strength of the Company's razor-razorblade business model. The anticipated
results reflect ongoing enhancements in the Company's sales mix, with higher-margin consumables continuing to account for an increasing
share of total revenue.
preliminary unaudited revenue results for the fiscal first quarter ended September 30, 2025, are based on information available to management
as of the date of this press release and are, therefore, subject to adjustments based on the Company's completion of its quarter-end
financial close process. The Company expects to disclose financial results for the fiscal first quarter ended September 30, 2025, in
its upcoming Quarterly Report on Form 10-Q, expected to be filed with the Securities and Exchange Commission during the week commencing
Intelligent Bio Solutions Inc.
Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The
Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat
analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the
test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis.
With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical
industries. The Company's current customer segments outside the U.S. include construction, manufacturing and engineering, transport
and logistics firms, mining, drug treatment organizations, and coroners.
more information, visit https://ibs.inc/
of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section
21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties.
Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.'s ability to successfully
develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure
regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking
statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or
implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology,
including "believes," "estimates," "anticipates," "expects," "plans," "projects,"
"intends," "potential," "may," "could," "might," "will," "should,"
"approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements.
These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent
Bio Solutions' public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this
release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained
in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Pinto, Managing Director
KCSA Strategic Communications